Business
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation proteome analysis platform to advance the study
About this update from Nautilus Biotechnology, Inc.
[{"type":"text","content":"Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation proteome analysis platform to advance the study of a rare childhood cancer\nSEATTLE, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute (TGen), part of City of Hope, today announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma (DIPG), a rare and often fatal childhood cancer. The goal of the partnership between Nautilus and TGen is to better understand the epigenetic mechanisms at work in DIPG by interrogating the proteoform landscape of specific proteins at the single-molecule level. In doing so, TGen plans to explore the combination of alterations and modifications present on these proteins (proteoforms) that are not possible to detect by peptide-based protein analysis methods. This collaboration represents the fifth early collaboration program for Nautilus as it advances towards broader platform access in 2023 and commercial launch in 2024. “In line with our strategy to collaborate throughout the development process of our platform, we are excited to begin piloting single-molecule applications of our technology with the incredibly motivated and talented research team at TGen,” said Nick Nelson, Chief Business Officer at Nautilus Biotechnology. “TGen has long been a pioneer in the field of oncology precision medicine, and we’re looking forward to building on this partnership to help pave the way for single-molecule proteomics to deliver new insights in cancer research.” “We are excited to work with Nautilus in being able to characterize the proteome in DIPG to further our understanding of this aggressive brain cancer,” said Dr. Stephanie Pond, Vice President of Emerging Opportunities at TGen. DIPG is a brain tumor that occurs in an area of the brainstem (the pons) which controls many of the body’s most vital functions such as breathing, blood pressure, and heart rate. Because of its location in the brain and how rapidly it progresses, DIPG is difficult to treat and is regarded as a high-grade malignant brain tumor. DIPG is characterized by specific mutations in genes coding ...